Is Lucid Diagnostics Inc. (LUCD) a Buy, Sell, or Hold?
Lucid Diagnostics Inc.
NASDAQ:LUCD
$1.055 USD
$0.05 (5.5%)
- Volume
- 788.3K
- Average Volume
- 1.26M
- Market Capitalization
- $107.93M
- P/E Ratio
- -2.26
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $1.63
- Year Low
- $0.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.07
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lishan Aklog |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | LUCD |
| CUSIP | 54948X109 |
| CIK | 0001799011 |
| Web | https://www.luciddx.com |
| Phone | 212 949 4319 |
| Currency | USD |
| Employees | 82 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 6.70 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.07 |
| Quick Ratio | 1.03 |
| Cash Ratio | 0.95 |
Sales & Book Value
| Annual Sales | $4.71M |
| Price / Sales | 21.02 |
| Cash Flow | -0.46 |
| Price / Cash Flow | -2.32 |
| Price / Book | 26.89 |
Price Target and Rating
| Average Stock Price Forecast | $2.00 |
| High Stock Price Forecast | $2.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | -47.25% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.69 |
| Trailing P/E Ratio | -2.26 |
| PEG Ratio | -0.02 |
| P/E Growth | -0.02 |
| Net Income | $-58.01M |
| Net Margin | -876.72% |
| Pretax Margin | -876.72% |
| Return on Equity | -370.21% |
| Return on Assets | -132.07% |
Financials Score
| AltmanZ Score | -14.38 |
| Piotroski Score | 2.00 |
| Working Capital | 1.98M |
| Total Assets | 34.08M |
| Ebit | -44.99M |
| Market Cap | 100.25M |
| Total Liabilities | 30.08M |
Poll Results
About Lucid Diagnostics Inc. (NASDAQ:LUCD) Stock
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc. ...
Lucid Diagnostics: Positioned For A Medicare-Driven Inflection
2026-07-03 10:03:31
Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection point unlocking a $2–3M backlog and accelerating $8.7M quarterly billable demand. Strong underlying test volume growth, expanding VA access to 9M patients at $1,938/test, and a cash runway into 2027 support LUCD's commercial trajectory. Despite a 1Q26 net loss of $23.6M (impacted by a $9.7M preferred dividend), the non-GAAP loss was $10.5M, reflecting stable underlying cost control and $45M pro forma cash.
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-24 12:12:14
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15 08:00:00
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing Conference call and webcast to be held today, May 15, at 8:30 AM EDT NEW YORK, May 15, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the first quarter ended March 31, 2026. Conference Call and Webcast The webcast will take place on Friday, May 15, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
2026-05-14 16:30:45
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Q1 Earnings Call Highlights
2026-05-14 13:10:18
Lucid Diagnostics NASDAQ: LUCD reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health systems.
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
2026-05-14 10:25:34
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.16 per share a year ago.
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-14 08:00:00
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May 14, at 8:30 AM EDT NEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the first quarter ended March 31, 2026. Conference Call and Webcast The webcast will take place on Thursday, May 14, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
2026-05-08 11:01:06
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Frequently Asked Questions
-
What is the current Lucid Diagnostics Inc. (LUCD) stock price?
-
Lucid Diagnostics Inc.(NASDAQ:LUCD) stock price is $1.055 in the last trading session. During the trading session, LUCD stock reached the peak price of $1.629 while $0.9 was the lowest point it dropped to. The percentage change in LUCD stock occurred in the recent session was 5.5% while the dollar amount for the price change in LUCD stock was $0.05.
-
LUCD's industry and sector of operation?
-
The NASDAQ listed LUCD is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of LUCD?
-
Brian J. deGuzman | Chief Technology & Compliance Officer
Dennis McGrath | Chief Financial Officer
Danielle W. Scelfo | Senior Vice President of Market Access & Government Affairs
Lishan Aklog | Chairman & Chief Executive Officer
Suman Verma | Senior VP & Chief Scientific Officer -
How many employees does LUCD have?
-
Number of LUCD employees currently stands at 82. LUCD operates from One Grand Central Place, New York City, NY 10165, US.
-
Link for LUCD official website?
-
Official Website of LUCD is: https://www.luciddx.com
-
How do I contact LUCD?
-
LUCD could be contacted at phone #212 949 4319 and can also be accessed through its website. LUCD operates from One Grand Central Place, New York City, NY 10165, US.
-
How many shares of LUCD are traded daily?
-
The average number of LUCD shares traded daily for last 3 months was 1.26M.
-
What is the market cap of LUCD currently?
-
The market value of LUCD currently stands at $107.93M with its latest stock price at $1.055